Paratek Announces Appointment of Minnie Baylor-Henry to its Board of Directors

Paratek focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

FREMONT, CA: Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company recently appointed Minnie Baylor-Henry, J.D., a recognized leader in the area of food and drug laws and regulations to the company’s Board of Directors. The firm focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.

“We are delighted to welcome Minnie to Paratek’s Board of Directors,” said Michael Bigham, Chairman of the Board, Paratek. “She brings extensive expertise and unique perspectives from her work with top global businesses, government agencies and leading non-profit organizations that will be invaluable as we continue to pursue life cycle initiatives for NUZYRA and continue our commitment to supporting the fight against antimicrobial resistance.”

Minnie is the president of B-Henry & Associates, a consulting firm that helps life sciences companies with regulatory and compliance strategies. Minnie previously worked for Johnson & Johnson (J&J), most recently as Worldwide Vice-President for Regulatory Affairs for J&J’s Medical Devices & Diagnostics business, and at Deloitte & Touche as a National Director for Regulatory & Capital Markets Consulting. Minnie began her career at J&J after working for the U.S. Food and Drug Administration (FDA).

“Paratek has established NUZYRA as one of the most successful antibiotics launched in the last five years and I look forward to helping guide the company through its next phase of growth and development,” commented Minnie. “It is an exciting time to join the Board given the recent expansion of NUZYRA into the community setting, the companys ongoing research into NUZYRAs potential against biothreat pathogens including anthrax and their plans to start a Phase 2b study exploring NUZYRA as a possible treatment for Non-Tuberculous Mycobacteria (NTM) infections.”

She previously served as the Board Chair for the Food and Drug Law Institute (FDLI). She also served as President and Chair of the Board of Directors for the Drug Information Association (DIA), where she is now a Fellow. Minnie is the Chair of the Board of Visitors at Howard University’s College of Pharmacy and a Trustee for Howard University. She also serves on the boards of scPharmaceuticals, Apyx Medical, and PolarityTE, all of which are publicly traded companies. Flame Biosciences, a clinical-stage biopharmaceutical startup, has appointed her as an Independent Director. In addition, Minnie sits on the boards of various non-profit organizations, including The Partnership, Mass Eye and Ear Hospital, and Dress for Success Boston. She earned her bachelor’s degree in pharmacy from Howard University and her law degree from Catholic University’s Columbus School of Law.